

ETEC Diarrhea: Global Health Problem for LDCs

Gregory M. Glenn, M.D. Chief Scientific Officer December 12, 2008

Intercell develops vaccines for the prevention and treatment of infectious diseases.

For more information be invited to: www.intercell.com



Conflicts of Interest

Intercell is developing a vaccine patch for travelers' diarrhea Gregory Glenn is an employee and stockholder of Intercell

PAGE 1 FDAA CONFIDENTIAL 12 December 2008



Qualifying criteria for tropical disease applications under section 524


Product for prevention or treatment of listed neglected tropical diseases or other infectious disease for which:

- » There is no significant market in developed nations
- » That disproportionately affects poor and marginalized populations

PAGE 2 FDAA CONFIDENTIAL 12 December 2008



Diarrheal Disease: A Major Burden and Unmet Need in Global Child Health



 $http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_part2.pdf$



Diarrheal Disease: A Major Burden and Unmet Need in Global Child Health

Causes of death among children aged under five years

Six causes of death account for 73% of the 10.4 million deaths among children under the age of five years worldwide (Figure 5):

- acute respiratory infections, mainly pneumonia (17%)
- diarrhoeal diseases (17%)
- prematurity and low birth weight (11%)
- neonatal infections such as sepsis (9%)
- birth asphyxia and trauma (8%)
- malaria (7%).

http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_part2.pdf




Investment in Diarrheal Disease Research in LDCs

Disease Burden vs. Health Care Investment

Limited developing world health care expenditures highlight global inequities

- The burden of disease in developing countries outstrips budgets for health care.
- Despite a pressing global burden, R&D spending on neglected diseases is far less than for Western diseases with similar mortality and morbidity profiles.

R&D Spending per DALY



DALY: Disability Adjusted Life Year
The number of healthy years of life lost due to premature death and disability


http://www.bvgh.org/innovation/crisis/GlobalHealthChallenge.asp



ETEC Diarrhea in Infants and Children in LDCs

- •Enterotoxigenic E. coli (ETEC) diarrhea
 - •Follows ingestion of contaminated food or water
 - •1.1 billion have no access to safe drinking water*
 - •Leads to profuse, watery diarrhea lasting several days
 - •Can lead to dehydration in young children in LDCs
- •ETEC Distribution: risk distribution similar to traveler's diarrhea

Risk Areas for Traveler's Diarrhea



^{*}i. Mara, D.D. 2003. Water, sanitation and hygiene for the health of developing nations. Public Health. 117:452–456.

PAGE 6 CONFIDENTIAL 12 December 2008



ETEC and Global Diarrhea Mortality

- Enterotoxigenic E. coli (ETEC) diarrhea mortality
 - •Overall global mortality has declined from 4.6 to 1.6 due to ORS in past decade
 - •Currently estimated 200 million cases of ETEC in LDC children <5 years of age
 - Leading cause of diarrhea
 - Second only to rotavirus in dehydrating diarrhea
 - •Estimated 380-500,000 deaths annually due to ETEC

http://www.who.int/vaccine research/diseases/e e coli/en/




Figure 1

Worldwide distribution of deaths caused by diarrhea in children under 5 years of age in 2000. Although global mortality from diarrhea has declined in recent years, from approximately 4.6 million deaths during the mid-1980s to the current estimate of 1.6–2.1 million, most of these deaths occur in children in developing countries under the age of 5 years. Data are from the year 2000 (2).

The Journal of Clinical Investigation http://www.jci.org Volume 118 Number 4 April 2008

PAGE 7 FDAA CONFIDENTIAL 12 December 2008



Guatemala: Example of Diarrhea as a Global Health Problem in an LDC

Causes of death in children under-5


Caubes of acati in cimaren anaer s		
Distribution of causes of death among children under 5 years of age Guatemala, 2000-2003		
	Deaths ^b	Regional average
Causes	(%)	(%)
Total neonatal deaths	100	100
Neonatal causes ^a	37	44
HIV/AIDS	3	1
Diarrhoeal diseases	13	10
Measles	0	0
Malaria	0	0
Pneumonia	15	12
Injuries	2	5
Others	30	28

- a. Includes diarrhoea during neonatal period
- Sum of individual proportions may not add up to 100% due to rounding.

http://www.who.int/whosis/mort/profiles/mort_amro_gtm_guatemala.pdf



Etiology of Severe Diarrhea in Guatemalan Children



Olga Torres (Guatemala) presented to WHO working group, October 2006 Gothenburg,

PAGE 9 FDAA CONFIDENTIAL 12 December 2008



Morbidity Due to Diarrhea

- Enterotoxigenic E. coli (ETEC) diarrhea morbidity
 - •Overall global morbidity from diarrhea unchanged in past decades
 - •Diarrheal bout in the first 2 years of life:
 - Disrupts absorptive function of GI tract
 - •Brain and synapse development occurs in first 2 years of life
 - •Growth stunting, IQ loss, fitness for schooling, other effects
 - •Estimated 200 million cases of ETEC in children <5 years of age
 - ETEC most common etiology in many settings
 - Repeat bouts common





Review series

Enteric infections, diarrhea, and their impact on function and development

William A. Petri Jr., 1 Mark Miller, 2 Henry J. Binder, 3 Myron M. Levine, 4 Rebecca Dillingham, 1 and Richard L. Guerrant 1

Center for Global Health, Divisio: J. Clin. Invest. 118:1277–1290 (2008). dicine, Charlottesville, Virginia, USA. ²Fogarty In ⁴Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA.

www.umich.edu/.../img/ Cholera-Babies-&-Diet.j

PAGE 10 CONFIDENTIAL 12 December 2008




Intercell Vaccine Approach to Traveler's Diarrhea

Vaccine Antigen

•LT, the heat labile toxin from E. coli

Toxin-The Key Pathogenic Factor


- •Binds to, and activates mucosal epithelial cells
- Causes fluid dysregulation via chloride channels
 - Results in fluid secretion in the gut
- •Disrupts the mucosal barrier, aids colonization by *E. coli* and other organisms
- •Toxins are the classic approach to vaccination with a historic impact on disease
- •Hypothesis: Immunity to LT neutralizes the toxin effects, will prevent and ameliorate diarrhea



PAGE 11 CONFIDENTIAL 12 December 2008



Transcutaneous Immunization: Vaccine Delivery to the Skin



PAGE 12

FDAA

CONFIDENTIAL

12 December 2008



Intercell TD Patch System


LT Patch

- » Needle-free
- » Simple to apply, flexible for addition to EPI schedule
- » Dry, with stabilizing excipient formulation
 - Stable under harsh conditions, ie for shipping, shelf storage
- » Process scaled for manufacturing





LT Patch Efficacy Against Clinically Significant Diarrheal Episodes in Travelers



Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial

Sarah A Frech, Herbert L DuPont, A Lauis Bourgeois, Robin McKenzie, Jaime Belkind-Genon, Jose F Figueroa, Pablo C Okhuysen, Norma H Guerre Francisco G Martiner-Sandoval, Juan H M Melénder-Romero, Zhi-Dong Jiang, Edwin J Astunias, Jane Holpern, Olga R Torres, Ana S Hoffman, Christina P Villas, Raniva M Kassen, David C Frex. B H Andersen. Kazem Kazemour. Salv A Breisch. Greenow M Glenn

Frech et al: Lancet 371, 2008



ETEC Vaccine Patch

- •Potentially efficacious vaccine against ETEC for children
- » Protection extending beyond ETEC
- •Needle-free, ambient temperature stable patch vaccine
- •Benefits of pediatric vaccine extend to decreased mortality and morbidity





No Significant Market

- » Little or no ETEC disease in developed countries
- » TD market is for travelers, typically 18 years of age and up, running the range from retirees down to students studying languages, taking Spring breaks, or participating in service projects
- » Developing an ETEC vaccine for children in endemic countries means targeting children at weaning age and up (from 3 to 5 months of age)
 - Product likely to be different from the adult TD vaccine in dose, formulation and size.
- » No significant market for a pediatric formulation in developed nations

"Any other infectious disease for which there is no significant market in developing nations And that disproportionately affects poor and marginalized populations..."

PAGE 16 CONFIDENTIAL 12 December 2008



Qualifying criteria for tropical disease applications under section 524 – ETEC

Product for prevention or treatment of listed neglected tropical diseases or other infectious disease for which:

- » There is no significant market in developed nations
 - No current ETEC vaccine for infants
 - No market opportunity for infants from developed world
- » That disproportionately affects poor and marginalized populations
 - ETEC is major child global health problem in the LDCs
 - Mortality
 - Morbidity
 - No current product addresses ETEC

PAGE 17 FDAA CONFIDENTIAL 12 December 2008



Conclusions

- » ETEC diarrhea is a global health problem affecting the most vulnerable and marginalized populations
- » No significant market for a pediatric ETEC patch
- » Intercell requests that ETEC diarrhea will be added to the list of Designated Tropical Diseases to the FDAA

FDAA CONFIDENTIAL 12 December 2008

